CV Therapeutics Inc.'s regadenoson to boost coronary blood flow for better myocardial perfusion imaging hit the primary endpoint in the first of two pivotal Phase III studies, and the company is awaiting results from the second trial. (BioWorld Today)

Having found no new cases of progressive multifocal leukoencephalopathy in a completed safety review of Tysabri patients, Biogen Idec Inc. and Elan Corp. plc said they hope to get the multiple sclerosis drug back on the market, with regulatory paperwork to be filed in the fall. (BioWorld Today)

After giving up on its migraine drug MT 100 last week, Pozen Inc. has submitted a new drug application for another therapy targeting the same condition - Trexima, which is a pill that combines sumatriptan succinate and one of MT 100's ingredients, naproxen sodium. (BioWorld Today)

The old adage - seldom spoken in our more enlightened, animal-sensitive times - about there being "more than one way to skin a cat" might have come to mind last week when CollaGenex Pharmaceuticals Inc. disclosed its plan to get around a generic threat to Periostat for gum disease.

Protein Design Labs Inc. nailed down the whopper deal of the year so far with Biogen Idec Inc., which is paying $40 million up front, buying $100 million in equity, and promising up to $660 million in milestones related to three Phase II compounds. (BioWorld Today)